Abstract
A potentially promising treatment of metastatic cancer is the systemic delivery of oncolytic adenoviruses. This requires engineering viruses which selectively replicate in tumors. We have constructed such an oncolytic adenovirus, OAS403, in which two early region genes are under the control of tumor-selective promoters that play a role in two key pathways involved in tumorigenesis. The early region E1A is controlled by the promoter for the E2F-1 gene, a transcription factor that primarily upregulates genes for cell growth. The E4 region is under control of the promoter for human telomerase reverse transcriptase, a gene upregulated in most cancer cells. OAS403 was evaluated in vitro on a panel of human cells and found to elicit tumor-selective cell killing. Also, OAS403 was less toxic in human hepatocyte cultures, as well as in vivo when compared to an oncolytic virus that lacked selective E4 control. A single intravenous injection of 3 × 1012 vp/kg in a Hep3B xenograft mouse tumor model led to significant antitumor efficacy. Additionally, systemic administration in a pre-established LNCaP prostate tumor model resulted in over 80% complete tumor regressions at a tolerable dose. Vector genome copy number was measured in tumors and livers at various times following tail vein injection and showed a selective time-dependent increase in tumors but not livers over 29 days. Furthermore, efficacy was significantly improved when OAS403 treatment was combined with doxorubicin. This virus holds promise for the treatment of a broad range of human cancers including metastatic disease.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Alemany R, Balague C, Curiel DT . Replicative adenoviruses for cancer therapy. Nat Biotechnol. 2000;18:723–727.
Hallenbeck PL, Chang YN, Hay C, et al. A novel tumor-specific replication-restricted adenoviral vector for gene therapy of hepatocellular carcinoma. Hum Gene Ther. 1999;10:1721–1733.
Hawkins LK, Lemoine NR, Kirn D . Oncolytic biotherapy: a novel therapeutic platform. Lancet Oncol. 2002;3:17–26.
Jakubczak JL, Ryan P, Gorziglia M, et al. An oncolytic adenovirus selective for retinoblastoma tumor suppressor protein pathway-defective tumors: dependence on E1A, the E2F-1 promoter, and viral replication for selectivity and efficacy. Cancer Res. 2003;63:1490–1499.
Russell WC . Update on adenovirus and its vectors. J Gen Virol. 2000;81(Part 11):2573–2604.
Kurihara T, Brough DE, Kovesdi I, Kufe DW . Selectivity of a replication-competent adenovirus for human breast carcinoma cells expressing the MUC1 antigen. J Clin Invest. 2000;106:763–771.
Matsubara S, Wada Y, Gardner TA, et al. A conditional replication-competent adenoviral vector, Ad-OC-E1a, to cotarget prostate cancer and bone stroma in an experimental model of androgen-independent prostate cancer bone metastasis. Cancer Res. 2001;61:6012–6019.
Peng XY, Won JH, Rutherford T, et al. The use of the L-plastin promoter for adenoviral-mediated, tumor-specific gene expression in ovarian and bladder cancer cell lines. Cancer Res. 2001;61:4405–4413.
Rodriguez R, Schuur ER, Lim HY, Henderson GA, Simons JW, Henderson DR . Prostate attenuated replication competent adenovirus (ARCA) CN706: a selective cytotoxic for prostate-specific antigen-positive prostate cancer cells. Cancer Res. 1997;57:2559–2563.
Ganly I, Kirn D, Eckhardt G, et al. A phase I study of Onyx-015, an E1B attenuated adenovirus, administered intratumorally to patients with recurrent head and neck cancer. Clin Cancer Res. 2000;6:798–806.
Khuri FR, Nemunaitis J, Ganly I, et al. A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. Nat Med. 2000;6:879–885.
DeWeese TL, van der PH, Li S, et al. A phase I trial of CV706, a replication-competent, PSA selective oncolytic adenovirus, for the treatment of locally recurrent prostate cancer following radiation therapy. Cancer Res. 2001;61:7464–7472.
Kirn D, Martuza RL, Zwiebel J . Replication-selective virotherapy for cancer: Biological principles, risk management and future directions. Nat Med. 2001;7:781–787.
Nemunaitis J, Khuri F, Ganly I, et al. Phase II trial of intratumoral administration of ONYX-015, a replication-selective adenovirus, in patients with refractory head and neck cancer. J Clin Oncol. 2001;19:289–298.
Tauber B, Dobner T . Adenovirus early E4 genes in viral oncogenesis. Oncogene. 2001;20:7847–7854.
Gorziglia MI, Lapcevich C, Roy S, et al. Generation of an adenovirus vector lacking E1, E2a, E3, and all of E4 except open reading frame 3. J Virol. 1999;73:6048–6055.
Halbert DN, Cutt JR, Shenk T . Adenovirus early region 4 encodes functions required for efficient DNA replication, late gene expression, and host cell shutoff. J Virol. 1985;56:250–257.
Kaelin WGJ . Functions of the retinoblastoma protein. BioEssays. 1999;21:950–958.
Trimarchi JM, Lees JA . Sibling rivalry in the E2F family. Nat Rev Mol Cell Biol. 2002;3:11–20.
Dyson N . The regulation of E2F by pRB-family proteins. Genes Dev. 1998;12:2245–2262.
Adams PD, Kaelin WGJ . Transcriptional control by E2F. Semin Cancer Biol. 1995;6:99–108.
Zwicker J, Muller R . Cell cycle-regulated transcription in mammalian cells. Prog Cell Cycle Res. 1995;1:91–99.
Nakayama J, Tahara H, Tahara E, et al. Telomerase activation by hTRT in human normal fibroblasts and hepatocellular carcinomas. Nat Genet. 1998;18:65–68.
Takakura M, Kyo S, Kanaya T, et al. Cloning of human telomerase catalytic subunit (hTERT) gene promoter and identification of proximal core promoter sequences essential for transcriptional activation in immortalized and cancer cells. Cancer Res. 1999;59:551–557.
Meyerson M, Counter CM, Eaton EN, et al. hEST2, the putative human telomerase catalytic subunit gene, is up-regulated in tumor cells and during immortalization. Cell. 1997;90:785–795.
Gunes C, Lichtsteiner S, Vasserot AP, Englert C . Expression of the hTERT gene is regulated at the level of transcriptional initiation and repressed by Mad1. Cancer Res. 2000;60:2116–2121.
Kolquist KA, Ellisen LW, Counter CM, et al. Expression of TERT in early premalignant lesions and a subset of cells in normal tissues. Nat Genet. 1998;19:182–186.
Poole JC, Andrews LG, Tollefsbol TO . Activity, function, and gene regulation of the catalytic subunit of telomerase (hTERT). Gene. 2001;269:1–12.
Braunstein I, Cohen-Barak O, Shachaf C, et al. Human telomerase reverse transcriptase promoter regulation in normal and malignant human ovarian epithelial cells. Cancer Res. 2001;61:5529–5536.
Gu J, Kagawa S, Takakura M, et al. Tumor-specific transgene expression from the human telomerase reverse transcriptase promoter enables targeting of the therapeutic effects of the Bax gene to cancers. Cancer Res. 2000;60:5359–5364.
Komata T, Kondo Y, Kanzawa T, et al. Treatment of malignant glioma cells with the transfer of constitutively active caspase-6 using the human telomerase catalytic subunit (human telomerase reverse transcriptase) gene promoter. Cancer Res. 2001;61:5796–5802.
Komata T, Kondo Y, Kanzawa T, et al. Caspase-8 gene therapy using the human telomerase reverse transcriptase promoter for malignant glioma cells. Hum Gene Ther. 2002;13:1015–1025.
Majumdar AS, Hughes DE, Lichtsteiner SP, Wang Z, Lebkowski JS, Vasserot AP . The telomerase reverse transcriptase promoter drives efficacious tumor suicide gene therapy while preventing hepatotoxicity encountered with constitutive promoters. Gene Therapy. 2001;8:568–578.
Kim E, Kim JH, Shin HY, Lee H, Yang JM, Kim J, et al. Ad-mTERT-delta19, a conditional replication-competent adenovirus driven by the human telomerase promoter, selectively replicates in and elicits cytopathic effect in a cancer cell-specific manner. Hum Gene Ther. 2003;14:1415–1428.
Huang TG, Savontaus MJ, Shinozaki K, Sauter BV, Woo SL . Telomerase-dependent oncolytic adenovirus for cancer treatment. Gene Therapy. 2003;10:1241–1247.
Irving J, Wang Z, Powell S, et al. Conditionally replicative adenovirus driven by the human telomerase promoter provides broad-spectrum antitumor activity without liver toxicity. Cancer Gene Ther. 2004;11:174–185.
Farshid M, Hsia CC, Tabor E . Alterations of the RB tumour suppressor gene in hepatocellular carcinoma and hepatoblastoma cell lines in association with abnormal p53 expression. J Viral Hepat. 1994;1:45–53.
Spillare EA, Okamoto A, Hagiwara K, et al. Suppression of growth in vitro and tumorigenicity in vivo of human carcinoma cell lines by transfected p16INK4. Mol Carcinog. 1996;16:53–60.
Thalmann GN, Sikes RA, Wu TT, et al. LNCaP progression model of human prostate cancer: androgen-independence and osseous metastasis. Prostate. 2000;44:91–103.
Korenchuk S, Lehr JE, MClean L, et al. VCaP, a cell-based model system of human prostate cancer. In Vivo. 2001;15:163–168.
Young CSH, Shenk T, Ginsberg HS . The Genetic System. In: Ginsberg HS, ed. The Adenoviruses. New York: Plenum Press; 1984: 125–172.
Chartier C, Degryse E, Gantzer M, Dieterle A, Pavirani A, Mehtali M . Efficient generation of recombinant adenovirus vectors by homologous recombination in Escherichia coli. J Virol. 1996;70:4805–4810.
He TC, Zhou S, da Costa LT, Yu J, Kinzler KW, Vogelstein B . A simplified system for generating recombinant adenoviruses. Proc Natl Acad Sci USA. 1998;95:2509–2514.
Jakubczak JL, Rollence ML, Stewart DA, et al. Adenovirus type 5 viral particles pseudotyped with mutagenized fiber proteins show diminished infectivity of coxsackie B-adenovirus receptor-bearing cells. J Virol. 2001;75:2972–2981.
Mittereder N, March KL, Trapnell BC . Evaluation of the concentration and bioactivity of adenovirus vectors for gene therapy. J Virol. 1996;70:7498–7509.
Smith T, Idamakanti N, Kylefjord H, et al. In vivo hepatic adenoviral gene delivery occurs independently of the coxsackievirus-adenovirus receptor. Mol Ther. 2002;5:770–779.
Paielli DL, Wing MS, Rogulski KR, et al. Evaluation of the biodistribution, persistence, toxicity, and potential of germ-line transmission of a replication-competent human adenovirus following intraprostatic administration in the mouse. Mol Ther. 2000;1:263–274.
Parr MJ, Manome Y, Tanaka T, et al. Tumor-selective transgene expression in vivo mediated by an E2F-responsive adenoviral vector. Nat Med. 1997;3:1145–1149.
Kelly WR . The liver and biliary system. In: Jubb KVF, Kennedy PC, Palmer N, eds. Pathology of Domestic Animals. 4th edn. New York: Academic Press; 1993: 319–406.
Mansfield K, King N . Viral Diseases. In: Bennett BT, Abee CR, Henrickson R, eds. Nonhuman Primates in Biomedical Research. New York: Academic Press; 1998: 1–57.
Porter HJ, Padfield CJ, Peres LC, Hirschowitz L, Berry PJ . Adenovirus and intranuclear inclusions in appendices in intussusception. J Clin Pathol. 1993;46:154–158.
Greenberg RA, Allsopp RC, Chin L, Morin GB, DePinho RA . Expression of mouse telomerase reverse transcriptase during development, differentiation and proliferation. Oncogene. 1998;16:1723–1730.
Yin L, Hubbard AK, Giardina C . NF-kappa B regulates transcription of the mouse telomerase catalytic subunit. J Biol Chem. 2000;275:36671–36675.
Smith TA, Mehaffey MG, Kayda DB, et al. Adenovirus mediated expression of therapeutic plasma levels of human factor IX in mice. Nat Genet. 1993;5:397–402.
Bristol JA, Shirley P, Idamakanti N, Kaleko M, Connelly S . In vivo dose threshold effect of adenovirus-mediated factor VIII gene therapy in hemophiliac mice. Mol Ther. 2000;2:223–232.
Tao N, Gao GP, Parr M, et al. Sequestration of adenoviral vector by Kupffer cells leads to a nonlinear dose response of transduction in liver. Mol Ther. 2001;3:28–35.
You L, Yang CT, Jablons DM . ONYX-015 works synergistically with chemotherapy in lung cancer cell lines and primary cultures freshly made from lung cancer patients. Cancer Res. 2000;60:1009–1013.
Yu DC, Chen Y, Dilley J, et al. Antitumor synergy of CV787, a prostate cancer-specific adenovirus, and paclitaxel and docetaxel. Cancer Res. 2001;61:517–525.
Li Y, Yu DC, Chen Y, et al. A hepatocellular carcinoma-specific adenovirus variant, CV890, eliminates distant human liver tumors in combination with doxorubicin. Cancer Res. 2001;61:6428–6436.
Habib NA, Sarraf CE, Mitry RR, et al. E1B-deleted adenovirus (dl1520) gene therapy for patients with primary and secondary liver tumors. Hum Gene Ther. 2001;12:219–226.
Bernt KM, Steinwaerder DS, Ni S, Li ZY, Roffler SR, Lieber A . Enzyme-activated prodrug therapy enhances tumor-specific replication of adenovirus vectors. Cancer Res. 2002;62:6089–6098.
Mi J, Li ZY, Ni S, Steinwaerder D, Lieber A . Induced apoptosis supports spread of adenovirus vectors in tumors. Hum Gene Ther. 2001;12:1343–1352.
Acknowledgements
We thank the GTI Histology, Molecular Biology, and Cell Biology Core Labs and the Laboratory Animal Services group for technical assistance. We also thank Dr Bill Kaelin for the E2F-1 promoter and helpful discussion. We gratefully acknowledge Dr Alex Matter, Novartis Oncology, for his guidance and support. This publication is fondly dedicated to the memory of our friend and colleague Pamela S Shirley.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Ryan, P., Jakubczak, J., Stewart, D. et al. Antitumor efficacy and tumor-selective replication with a single intravenous injection of OAS403, an oncolytic adenovirus dependent on two prevalent alterations in human cancer. Cancer Gene Ther 11, 555–569 (2004). https://doi.org/10.1038/sj.cgt.7700735
Received:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.cgt.7700735
Keywords
This article is cited by
-
Intelligent Design: Combination Therapy With Oncolytic Viruses
Molecular Therapy (2010)
-
A fully replication-competent adenovirus vector with enhanced oncolytic properties
Cancer Gene Therapy (2010)
-
A tunable dual‐promoter integrator for targeting of cancer cells
Molecular Systems Biology (2010)
-
A modified E2F-1 promoter improves the efficacy to toxicity ratio of oncolytic adenoviruses
Gene Therapy (2009)
-
E1A-expressing adenoviral E3B mutants act synergistically with chemotherapeutics in immunocompetent tumor models
Cancer Gene Therapy (2008)